Regenxbio to present interim update of RGX-314 Phase I/IIA trial
Category: #health  By Pankaj Singh  Date: 2019-08-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regenxbio to present interim update of RGX-314 Phase I/IIA trial
  • Dr. Jeffery Heier, the primary investigator of the trial, will present the data during the Retina Subspecialty day program held at AAO (American Academy of Ophthalmology) 2019 annual meeting, CA
     
  • The biotechnology firm is also planning to initiate a Phase 2b trial for wet AMD by the end of 2019

Regenxbio Inc., a U.S.-based leading clinical-stage biotechnology company has recently announced that an interim trial update from the Phase I/IIa clinical trial of RGX-314 which is targeted for treating wet AMD (age-related macular degeneration) will be reported at the American Academy of Ophthalmology (AAO) annual meeting in California, during a presentation at the Retina Subspecialty Day program.

As per sources close to the matter, Dr. Jeffery Heier, Director and Co-President of Retina Research at Ophthalmic Consultants & primary investigator of the trial, will present the interim results that include data for all 5 dose cohorts. 

According to Steve Pakola, M.D., Senior V.P. & CMO of Regenxbio, the company is elated by the previously announced positive interim data from the Phase I/IIa trial along with the potential of proprietary NAV® gene therapy as a one-time treatment for wet age-related macular degeneration.

He added that the company is looking forward to demonstrating data from all 5 dose cohorts from the clinical pilot in wet AMD at the coming American Academy of Ophthalmology meeting.

For the record, Regenxbio is a leading bio-technology company focused on improving lives through the potential of gene therapy. The firm’s NAV technology platform is a proprietary AAV (adeno-associated virus) gene delivery platform and consists of exclusive rights to more than 100 novel adeno-associated virus vectors, including AAVrh10, AAV9, AAV8 and AAV7.

Regenxbio and its third-party NAV technology platform licensees are also using NAV for the development of a wide pipeline of candidates in several therapeutic areas.

Source Credit: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-present-interim-phase-iiia-trial-update-rgx-314



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Emergency Care Partners finalizes its merger with Chicago’s IEMS
Emergency Care Partners finalizes its merger with Chicago’s IEMS
By Pankaj Singh

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which make...

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    By Pankaj Singh

    This is the second ANDA filed by both the companies, giving Elite Pharmaceutical the exclusive right to retail the drug.

    Elite Pharmaceuticals, Inc. a pharmaceutica...